Virbac completed the acquisition of the tilapia vaccines range of Ictyogroup. Therefore, Virbac will now be distributing and marketing both registered and autogenous tilapia vaccines globally.

Beyond the acquisition, the two companies have entered into a close partnership whereby Ictyogroup will continue to develop new vaccines and formulations for tilapia for Virbac’s AquaDivision and aquatic animal health business. The deal also includes the transfer from Ictyogroup to Virbac of several managers specialized in technical and marketing support and vaccine R&D in tilapia.

Cedric Komar, CEO of Ictyogroup said that “partnering with Virbac in the tilapia vaccine segment will clearly benefit the tilapia industry by matching Ictyogroup’s vaccine R&D excellence with Virbac’s worldwide marketing capabilities and customer dedication. Clearly, this deal brings the most complete and innovative tilapia vaccines to help the tilapia industry in Africa, Asia and Latin America.”

“This deal will assemble the best of two companies committed to the development of active solutions to meet the increasing demand for aquaculture. Tilapia is the aquaculture segment enjoying the fastest growth and will be one of the solutions to help feed fast-developing populations in the medium and long term. Thanks to this portfolio acquisition and continued partnership, Virbac, which is already a significant actor in the salmon and shrimp segments, will expand and complement its aquaculture operations in Africa, Asia and Latin America,” said Pierre Henning, director of Virbac Aquadivision.